Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology

Clinics in Liver Disease

Volumn 20, Issue 4, 2016, Pages 629-644

  Bengsch, Bertram ^a   Chang, Kyong Mi ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B and T cell responses to HBV; cccDNA; Hepatitis B virus; Immunobiology; Immunotherapy; Pathogenesis; Therapeutic vaccination; Translational hepatology

Indexed keywords

ALPHA INTERFERON; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; CYCLOSPORIN; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TENOFOVIR; UNCLASSIFIED DRUG; VIRAL PROTEIN; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN;

ANTIVIRAL THERAPY; B LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; DNA MODIFICATION; DRUG TARGETING; EFFECTOR CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MOLECULAR EVOLUTION; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION; VIROLOGY; VIRUS ENTRY; VIRUS IDENTIFICATION; VIRUS IMMUNITY; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; VACCINATION; VIRUS REPLICATION;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; VACCINATION; VIRUS REPLICATION;

EID: 84992212809     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2016.06.001     Document Type: Review

References (130)

1. 1 Alter, H.J., The road not taken or how I learned to love the liver: a personal perspective on hepatitis history. Hepatology 59 (2014), 4–12.
2. 2 Gerlich, W.H., Medical virology of hepatitis B: how it began and where we are now. Virol J, 10, 2013, 239.
3. 3 Thomas, E., Yoneda, M., Schiff, E.R., Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med, 5, 2015, a021345.
4. 4 Luerman, A., Eine icterusepidemie. Ber Klin Wochenschr, 1885, 20–23.
5. 5 McDonald, S., Acute yellow atrophy. Edinb Med J, 15, 1908, 108.
6. 6 Seeff, L.B., Beebe, G.W., Hoofnagle, J.H., et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 316 (1987), 965–970.
7. 7 Martin, N.A., The discovery of viral hepatitis: a military perspective. J R Army Med Corps 149 (2003), 121–124.
8. 8 MacCallum, F.O., Homologous serum jaundice. Lancet 2 (1947), 691–692.
9. 9 Krugman, S., Giles, J.P., Hammond, J., Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 200 (1967), 365–373.
10. 10 Melnick, J.L., Boggs, J.D., Human volunteer and tissue culture studies of viral hepatitis. Can Med Assoc J 106:Suppl (1972), 461–467.
11. 11 Blumberg, B.S., Alter, H.J., Visnich, S., A “new” antigen in leukemia sera. JAMA 191 (1965), 541–546.
12. 12 Blumberg, B.S., Gerstley, B.J., Hungerford, D.A., et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 66 (1967), 924–931.
13. 13 Okochi, K., Murakami, S., Observations on Australia antigen in Japanese. Vox Sang 15 (1968), 374–385.
14. 14 Prince, A.M., An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 60 (1968), 814–821.
15. 15 Blumberg, B.S., The discovery of the hepatitis B virus and the invention of the vaccine: a scientific memoir. J Gastroenterol Hepatol 17:Suppl (2002), S502–S503.
16. 16 Dane, D.S., Cameron, C.H., Briggs, M., Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1 (1970), 695–698.
17. 17 Almeida, J.D., Rubenstein, D., Stott, E.J., New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet 2 (1971), 1225–1227.
18. 18 Robinson, W.S., Clayton, D.A., Greenman, R.L., DNA of a human hepatitis B virus candidate. J Virol 14 (1974), 384–391.
19. 19 Robinson, W.S., Greenman, R.L., DNA polymerase in the core of the human hepatitis B virus candidate. J Virol 13 (1974), 1231–1236.
20. 20 Will, H., Cattaneo, R., Koch, H.G., et al. Cloned HBV DNA causes hepatitis in chimpanzees. Nature 299 (1982), 740–742.
21. 21 Beasley, R.P., Hwang, L.Y., Lin, C.C., et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet 2 (1981), 388–393.
22. 22 Krugman, S., Giles, J.P., Hammond, J., Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 218 (1971), 1665–1670.
23. 23 Hilleman, M.R., Buynak, E.B., Roehm, R.R., et al. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 270 (1975), 401–404.
24. 24 Purcell, R.H., Gerin, J.L., Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 270 (1975), 395–399.
25. 25 Maupas, P., Goudeau, A., Coursaget, P., et al. Immunisation against hepatitis B in man. Lancet 1 (1976), 1367–1370.
26. 26 Szmuness, W., Stevens, C.E., Harley, E.J., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303 (1980), 833–841.
27. 27 McAleer, W.J., Buynak, E.B., Maigetter, R.Z., et al. Human hepatitis B vaccine from recombinant yeast. Nature 307 (1984), 178–180.
28. 28 Poovorawan, Y., Sanpavat, S., Pongpunlert, W., et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 261 (1989), 3278–3281.
29. 29 Chang, M.H., You, S.L., Chen, C.J., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101 (2009), 1348–1355.
30. 30 Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 18 (2011), 369–375.
31. 31 Charnay, P., Pourcel, C., Louise, A., et al. Cloning in Escherichia coli and physical structure of hepatitis B virion DNA. Proc Natl Acad Sci U S A 76 (1979), 2222–2226.
32. 32 Pasek, M., Goto, T., Gilbert, W., et al. Hepatitis B virus genes and their expression in E. coli. Nature 282 (1979), 575–579.
33. 33 Valenzuela, P., Gray, P., Quiroga, M., et al. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280 (1979), 815–819.
34. 34 Magnius, L.O., Espmark, A., A new antigen complex co-occurring with Australia antigen. Acta Pathol Microbiol Scand B Microbiol Immunol 80 (1972), 335–337.
35. 35 Bruss, V., Gerlich, W.H., Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. Virology 163 (1988), 268–275.
36. 36 Standring, D.N., Ou, J.H., Masiarz, F.R., et al. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc Natl Acad Sci U S A 85 (1988), 8405–8409.
37. 37 Yim, H.J., Lok, A.S., Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 (2006), S173–S181.
38. 38 Raimondo, G., Pollicino, T., Romano, L., et al. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 58 (2010), 254–257.
39. 39 Lok, A.S., Everhart, J.E., Di Bisceglie, A.M., et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 54 (2011), 434–442.
40. 40 Rehermann, B., Ferrari, C., Pasquinelli, C., et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2 (1996), 1104–1108.
41. 41 Szmuness, W., Stevens, C.E., Ikram, H., et al. Prevalence of hepatitis B virus infection and hepatocellular carcinoma in Chinese-Americans. J Infect Dis 137 (1978), 822–829.
42. 42 Beasley, R.P., Hwang, L.Y., Lin, C.C., et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2 (1981), 1129–1133.
43. 43 Hohne, M., Schaefer, S., Seifer, M., et al. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J 9 (1990), 1137–1145.
44. 44 Kekule, A.S., Lauer, U., Meyer, M., et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 343 (1990), 457–461.
45. 45 Lucifora, J., Arzberger, S., Durantel, D., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55 (2011), 996–1003.
46. 46 Lau, C.C., Sun, T., Ching, A.K., et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 25 (2014), 335–349.
47. 47 Liang, H.W., Wang, N., Wang, Y., et al. Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122. J Hepatol 64 (2016), 278–291.
48. 48 Greenberg, H.B., Pollard, R.B., Lutwick, L.I., et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:10 (1976), 517–522.
49. 49 Marcellin, P., Ahn, S.H., Ma, X., et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150 (2016), 134–144.e10.
50. 50 Gerlich, W.H., Robinson, W.S., Hepatitis B virus contains protein attached to the 5’ terminus of its complete DNA strand. Cell 21 (1980), 801–809.
51. 51 Summers, J., Mason, W.S., Replication of the genome of a hepatitis B–like virus by reverse transcription of an RNA intermediate. Cell 29 (1982), 403–415.
52. 52 Nassal, M., Hepatitis B viruses: reverse transcription a different way. Virus Res 134 (2008), 235–249.
53. 53 Benhamou, Y., Dohin, E., Lunel-Fabiani, F., et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345 (1995), 396–397.
54. 54 Dienstag, J.L., Perrillo, R.P., Schiff, E.R., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 (1995), 1657–1661.
55. 55 Zoulim, F., Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver Int 31:Suppl 1 (2011), 111–116.
56. 56 Terrault, N.A., Bzowej, N.H., Chang, K.M., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
57. 57 Yan, H., Zhong, G., Xu, G., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 1, 2012, e00049.
58. 58 Volz, T., Allweiss, L., Ben, M.M., et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 58 (2013), 861–867.
59. 59 Watashi, K., Urban, S., Li, W., et al. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci 15 (2014), 2892–2905.
60. 60 Ni, Y., Lempp, F.A., Mehrle, S., et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146 (2014), 1070–1083.
61. 61 Watashi, K., Sluder, A., Daito, T., et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59 (2014), 1726–1737.
62. 62 Lin, S.R., Yang, H.C., Kuo, Y.T., et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids, 3, 2014, e186.
63. 63 Karimova, M., Beschorner, N., Dammermann, W., et al. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep, 5, 2015, 13734.
64. 64 Kennedy, E.M., Bassit, L.C., Mueller, H., et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476 (2015), 196–205.
65. 65 Ramanan, V., Shlomai, A., Cox, D.B., et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep, 5, 2015, 10833.
66. 66 Turelli, P., Mangeat, B., Jost, S., et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science, 303, 2004, 1829.
67. 67 Rosler, C., Kock, J., Kann, M., et al. APOBEC-mediated interference with hepadnavirus production. Hepatology 42 (2005), 301–309.
68. 68 Baumert, T.F., Rosler, C., Malim, M.H., et al. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 46 (2007), 682–689.
69. 69 Lucifora, J., Xia, Y., Reisinger, F., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
70. 70 Wieland, S.F., Chisari, F.V., Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79 (2005), 9369–9380.
71. 71 Wieland, S., Thimme, R., Purcell, R.H., et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101 (2004), 6669–6674.
72. 72 Dunn, C., Peppa, D., Khanna, P., et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137 (2009), 1289–1300.
73. 73 Lok, A.S., Ghany, M.G., Watson, G., et al. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 5 (1998), 171–178.
74. 74 Guidotti, L.G., Chisari, F.V., Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 (2006), 23–61.
75. 75 Fisicaro, P., Valdatta, C., Boni, C., et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58 (2009), 974–982.
76. 76 Hosel, M., Quasdorff, M., Wiegmann, K., et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50 (2009), 1773–1782.
77. 77 Guy, C.S., Mulrooney-Cousins, P.M., Churchill, N.D., et al. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 82 (2008), 8579–8591.
78. 78 Oliviero, B., Varchetta, S., Paudice, E., et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137 (2009), 1151–1160 1160.e1–7.
79. 79 Mondelli, M.U., Oliviero, B., Mele, D., et al. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. Front Immunol, 3, 2012, 351.
80. 80 Peppa, D., Gill, U.S., Reynolds, G., et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210 (2013), 99–114.
81. 81 Lang, P.A., Contaldo, C., Georgiev, P., et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 14 (2008), 756–761.
82. 82 Guidotti, L.G., Inverso, D., Sironi, L., et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 161 (2015), 486–500.
83. 83 Martinet, J., Dufeu-Duchesne, T., Bruder Costa, J., et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143 (2012), 1586–1596.e8.
84. 84 Martinet, J., Leroy, V., Dufeu-Duchesne, T., et al. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 56 (2012), 1706–1718.
85. 85 Dunn, C., Brunetto, M., Reynolds, G., et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204 (2007), 667–680.
86. 86 Pallett, L.J., Gill, U.S., Quaglia, A., et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med 21 (2015), 591–600.
87. 87 Tsutsumi, Y., Yamamoto, Y., Ito, S., et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 7 (2015), 2344–2351.
88. 88 Rehermann, B., Nascimbeni, M., Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 (2005), 215–229.
89. 89 Das, A., Ellis, G., Pallant, C., et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189 (2012), 3925–3935.
90. 90 Miller, D.J., Dwyer, J.M., Klatskin, G., Identification of lymphocytes in percutaneous liver biopsy cores. Different T: B cell ratio in HB sAg-positive and -negative hepatitis. Gastroenterology 72:6 (1977), 1199–1203.
91. 91 Ferrari, C., Penna, A., Bertoletti, A., et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145 (1990), 3442–3449.
92. 92 Bertoletti, A., Ferrari, C., Fiaccadori, F., et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 88 (1991), 10445–10449.
93. 93 Jung, M.C., Stemler, M., Weimer, T., et al. Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. Hepatology 13 (1991), 637–643.
94. 94 Penna, A., Chisari, F.V., Bertoletti, A., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174 (1991), 1565–1570.
95. 95 Missale, G., Redeker, A., Person, J., et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 177 (1993), 751–762.
96. 96 Maini, M.K., Boni, C., Ogg, G.S., et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117 (1999), 1386–1396.
97. 97 Thimme, R., Wieland, S., Steiger, C., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 (2003), 68–76.
98. 98 Xia, Y., Stadler, D., Lucifora, J., et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150 (2016), 194–205.
99. 99 Guidotti, L.G., Rochford, R., Chung, J., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999), 825–829.
100. 100 Boettler, T., Panther, E., Bengsch, B., et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80 (2006), 3532–3540.
101. 101 Maini, M.K., Boni, C., Lee, C.K., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000), 1269–1280.
102. 102 Zhang, Z., Zhang, J.Y., Wherry, E.J., et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134 (2008), 1938–1949 1949.e1–3.
103. 103 Kurktschiev, P.D., Raziorrouh, B., Schraut, W., et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med 211 (2014), 2047–2059.
104. 104 Boni, C., Fisicaro, P., Valdatta, C., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81 (2007), 4215–4225.
105. 105 Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36 (2015), 265–276.
106. 106 Fisicaro, P., Valdatta, C., Massari, M., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138 (2010), 682–693 693.e1–4.
107. 107 Fisicaro, P., Valdatta, C., Massari, M., et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143 (2012), 1576–1585.e4.
108. 108 Schurich, A., Khanna, P., Lopes, A.R., et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53 (2011), 1494–1503.
109. 109 Nebbia, G., Peppa, D., Schurich, A., et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One, 7, 2012, e47648.
110. 110 Cai, G., Nie, X., Li, L., et al. B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. J Gastroenterol 48 (2013), 1362–1372.
111. 111 Bengsch, B., Martin, B., Thimme, R., Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61 (2014), 1212–1219.
112. 112 Knolle, P.A., Thimme, R., Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146 (2014), 1193–1207.
113. 113 Iwai, Y., Terawaki, S., Ikegawa, M., et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198 (2003), 39–50.
114. 114 El-Khoueiry, A., Melero, I., Crocenzi, T., et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol, 33, 2015 Available at: http://meetinglibrary.asco.org/content/146146-156. Accessed July 22, 2016.
115. 115 Raziorrouh, B., Heeg, M., Kurktschiev, P., et al. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules. PLoS One, 9, 2014, e105703.
116. 116 Park, J.J., Wong, D.K., Wahed, A.S., et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150 (2016), 684–695.e5.
117. 117 Franzese, O., Kennedy, P.T., Gehring, A.J., et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 79 (2005), 3322–3328.
118. 118 Lopes, A.R., Kellam, P., Das, A., et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 118 (2008), 1835–1845.
119. 119 Schurich, A., Pallett, L.J., Lubowiecki, M., et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog, 9, 2013, e1003208.
120. 120 Das, A., Hoare, M., Davies, N., et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205 (2008), 2111–2124.
121. 121 Sandalova, E., Laccabue, D., Boni, C., et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143 (2012), 78–87.e3.
122. 122 Rehermann, B., Pasquinelli, C., Mosier, S.M., et al. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 96 (1995), 1527–1534.
123. 123 Dienstag, J.L., Stevens, C.E., Bhan, A.K., et al. Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. Ann Intern Med 96 (1982), 575–579.
124. 124 Liang, T.J., Block, T.M., McMahon, B.J., et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62 (2015), 1893–1908.
125. 125 Heathcote, J., McHutchison, J., Lee, S., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30 (1999), 531–536.
126. 126 Yang, S.H., Lee, C.G., Park, S.H., et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13 (2006), 1110–1117.
127. 127 Yoon, S.K., Seo, Y.B., Im, S.J., et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 35 (2015), 805–815.
128. 128 Gehring, A.J., Haniffa, M., Kennedy, P.T., et al. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 123 (2013), 3766–3776.
129. 129 June, C.H., Levine, B.L., T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci, 370, 2015, 20140374.
130. 130 Krebs, K., Bottinger, N., Huang, L.R., et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145 (2013), 456–465.